Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Eiko Lifesciences Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Option Chain
Analyzes market sentiment, predicts Eiko Lifesciences Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Eiko Lifesciences - Revised Financial Results For Quarter And Year Ended 31St March, 2025
-
Eiko Lifesciences - Revise Outcome Of Board Meeting Dated 14.05.2025
-
Eiko Lifesciences - Appointment Of Secretarial Auditor
-
Eiko Lifesciences - Appointment Of Internal Auditor
-
Eiko Lifesciences Q4 net profit zooms 190.32% at Rs 0.90 cr
-
Eiko Lifesciences - Results For Quarter And Year Ended 31St March 2025
-
Eiko Lifesciences - Board Meeting Outcome for Outcome Of Board Meeting Dated 14.05.2025
-
Eiko Lifesciences - Board Meeting Intimation for Approval Of Financial Results And Other Agendas
-
Eiko Lifesciences - Submission Of Initial And Annual Disclosure As Per SEBI Circular- - Fund Raising By Issuance Issuance Of
-
Eiko Lifesciences has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Eiko Lifesciences - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Eiko Lifesciences - Announcement under Regulation 30 (LODR)-Change in Directorate
Key fundamentals
Evaluate the intrinsic value of Eiko Lifesciences Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 58.1777 | 50.6783 | 29.4223 | 33.1827 | 14.2847 |
| Liabilities | 58.1777 | 50.6783 | 29.4223 | 33.1827 | 14.2847 |
| Equity | 13.7627 | 12.8728 | 8.3163 | 8.3163 | 3.82 |
| Gross Profit | 1.7094 | 1.6127 | 0.9545 | 1.2953 | 0.5218 |
| Net Profit | 1.7408 | 0.7515 | 0.7688 | 0.7057 | 0.6143 |
| Cash From Operating Activities | 2.046 | -7.0797 | 4.2238 | -7.7273 | -4.256 |
| NPM(%) | 5.35 | 2.69 | 4.19 | 2.77 | 5.12 |
| Revenue | 32.4918 | 27.9293 | 18.3214 | 25.4119 | 11.9905 |
| Expenses | 30.7824 | 26.3166 | 17.3669 | 24.1166 | 11.4687 |
| ROE(%) | 3.06 | 1.32 | 1.35 | 1.24 | 1.07 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Eiko Lifesciences Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Sugal and Damani Share Brokers Ltd | 69.72 | -4.99 | 11.98 | 31.46 | 36.98 | 0.00 |
| 360 One Wam Ltd | 1012.00 | 1.80 | 39.25 | 1806.70 | 2578.88 | 0.00 |
| Arman Holdings Ltd | 93.10 | 0.00 | 0.00 | 26.23 | 0.35 | 0.00 |
| Asia Capital Ltd | 17.37 | 4.95 | 16.86 | 15.57 | 6.62 | 0.00 |
Company Info
Narendra Investments (Delhi) Limited, incorporated on 7th January 1977, is an Investment Company listed on the Ahmedabad Stock Exchange and Delhi Stock Exchange Ltd.MAIN OBJECTS OF THE COMPANYTo carry on the business of an investment company and for that purpose to invest in, acquire, sell, transfer, subscribe for, hold and otherwise deal in and invest in any shares, bonds, stocks, obligations issued or guaranteed by any company constituted and carrying on business in India or elsewhere and debentures, debenture-stocks, bonds, obligations and securities issued or guaranteed by any Government, State, Sovereign, Commissioners Central or Provincial, public body or authority supreme, municipal, local or otherwise in India or elsewhere either out of its own funds or out of funds that it might borrow. 2016 -Listing of equity shares of Narendra Investments (Delhi) Ltd 2021 -Company name has changed to Eiko Lifesciences Ltd. from Narendra Investments (Delhi) Ltd.. 2023 -The company issued rights shares of Rs. 10 in the ratio of 2:3 at a premium of Rs. 35 per share. 2024 -The Company entered into definitive business agreement with Vivacious Pharmatex Private Limited.
Narendra Investments (Delhi) Limited, incorporated on 7th January 1977, is an Investment Company listed on the Ahmedabad Stock Exchange and Delhi Stock Exchange Ltd.MAIN OBJECTS OF THE COMPANYTo carry on the business of an investment company and for that purpose to invest in, acquire, sell, transfer, subscribe for, hold and otherwise deal in and invest in any shares, bonds, stocks, obligations issued or guaranteed by any company constituted and carrying on business in India or elsewhere and debentures, debenture-stocks, bonds, obligations and securities issued or guaranteed by any Government, State, Sovereign, Commissioners Central or Provincial, public body or authority supreme, municipal, local or otherwise in India or elsewhere either out of its own funds or out of funds that it might borrow. 2016 -Listing of equity shares of Narendra Investments (Delhi) Ltd 2021 -Company name has changed to Eiko Lifesciences Ltd. from Narendra Investments (Delhi) Ltd.. 2023 -The company issued rights shares of Rs. 10 in the ratio of 2:3 at a premium of Rs. 35 per share. 2024 -The Company entered into definitive business agreement with Vivacious Pharmatex Private Limited.
Read More
Parent Organisation
Eiko Lifesciences Ltd.
Founded
07/01/1977
Managing Director
NSE Symbol
FAQ
The current price of Eiko Lifesciences Ltd is
The 52-week high for Eiko Lifesciences Ltd is
The market capitalization of Eiko Lifesciences Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Eiko Lifesciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Eiko Lifesciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Eiko Lifesciences Ltd shares.
The CEO of Eiko Lifesciences Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
